Joint effects of serum ferritin and body mass index on the risk of coronary artery disease: a case-control study.

Yunping Zhou, Tongtao Liu, Chongqi Jia
Author Information
  1. Yunping Zhou: Department of Epidemiology and Health Statistics, Shandong University, Jinan, Shandong, People's Republic of China.

Abstract

OBJECTIVES: Serum ferritin and body mass index (BMI) have been reportedly associated with coronary artery disease (CAD) risk. The aim of the present study was to explore the interaction between serum ferritin and BMI on CAD risk.
DESIGN: Hospital-based case-control study.
SETTING: Patients with CAD and the controls were recruited from Qilu Hospital, Shandong University.
PARTICIPANTS: 258 CAD cases and 282 healthy controls.
METHODS: Multiplicative interaction was assessed through a cross-product interaction term in a multivariate logistic regression model. The effect of serum ferritin and BMI were evaluated per 50 µg/L and per 2 kg/m(2), respectively. The presence of additive interaction between serum ferritin and BMI was evaluated by calculation of the relative excess risk due to interaction (RERI), attributable proportion due to interaction (AP) and synergy index (S).
RESULTS: The ORs and 95% CI of the serum ferritin-BMI product term on a multiplicative scale in the univariate and multivariate models were 0.943 (0.904 to 0.984) and 1.004 (0.951 to 1.059), respectively. There was also evidence for interaction on an additive scale; the RERI (95% CI), AP (95% CI) and S (95% CI) in the univariate model were 0.314 (0.026 to 1.506), 0.107 (0.017 to 0.241) and 1.194 (1.053 to 1.406), respectively. After adjusting for the potential confounders, the estimates and 95% CIs for the aforementioned three measures were 0.004 (-0.016 to 0.311), 0.004 (-0.016 to 0.191) and 1.039 (0.774 to 1.285), respectively.
CONCLUSIONS: Serum ferritin and BMI had an additive interaction on the risk of CAD in Chinese population. Further investigations with big sample size are necessary for confirming this additive interaction.

Keywords

References

  1. FEBS Lett. 1998 Nov 6;438(3):159-60 [PMID: 9827537]
  2. Int J Mol Sci. 2011;12(5):3117-32 [PMID: 21686173]
  3. Circulation. 1998 Oct 6;98(14):1472-6 [PMID: 9760304]
  4. Lancet. 2006 Aug 19;368(9536):666-78 [PMID: 16920472]
  5. Eur J Epidemiol. 2005;20(7):575-9 [PMID: 16119429]
  6. Obes Rev. 2012 Feb;13(2):150-61 [PMID: 21981048]
  7. Lancet. 1981 Jun 13;1(8233):1293-4 [PMID: 6112609]
  8. Arch Intern Med. 2004 Feb 9;164(3):249-58 [PMID: 14769621]
  9. J Clin Invest. 2004 Dec;114(12):1752-61 [PMID: 15599400]
  10. Clin Biochem. 2012 Nov;45(16-17):1336-41 [PMID: 22728013]
  11. N Engl J Med. 2007 Jun 7;356(23):2388-98 [PMID: 17554120]
  12. Circulation. 2004 Apr 20;109(15):1877-85 [PMID: 15037530]
  13. Int J Cardiol. 2011 Oct 6;152(1):129-30 [PMID: 21856027]
  14. Epidemiology. 1996 May;7(3):286-90 [PMID: 8728443]
  15. Circulation. 1979 Mar;59(3):607-9 [PMID: 761341]
  16. Arterioscler Thromb Vasc Biol. 2003 Mar 1;23(3):368-70 [PMID: 12639824]
  17. Biochim Biophys Acta. 2009 Jul;1790(7):589-99 [PMID: 18929623]
  18. J Am Coll Cardiol. 2012 Oct 30;60(18):1715-21 [PMID: 23040572]
  19. J Am Coll Cardiol. 2013 Feb 5;61(5):553-60 [PMID: 23369419]
  20. Diabetes Care. 2011 Jun;34(6):1424-30 [PMID: 21602431]
  21. Eur J Clin Nutr. 1995 Jun;49(6):430-8 [PMID: 7656886]
  22. Arterioscler Thromb Vasc Biol. 2012 Oct;32(10):2525-30 [PMID: 22837473]
  23. J Am Coll Cardiol. 2013 Apr 16;61(15):1607-15 [PMID: 23500281]
  24. J Womens Health (Larchmt). 2009 Jun;18(6):795-801 [PMID: 19456248]
  25. PLoS Med. 2006 Nov;3(11):e442 [PMID: 17132052]
  26. Clin Biochem. 2008 Oct;41(14-15):1162-7 [PMID: 18692492]
  27. BMC Med. 2013 Apr 02;11:87 [PMID: 23547896]
  28. Epidemiol Perspect Innov. 2006 Apr 18;3:5 [PMID: 16620385]

Word Cloud

Created with Highcharts 10.0.00interaction1ferritinBMICADriskserum95%respectivelyadditiveCIindexstudy004Serumbodymasscoronaryarterycase-controlcontrolstermmultivariatemodelevaluatedper2dueRERIAPSscaleunivariate-0016OBJECTIVES:reportedlyassociateddiseaseaimpresentexploreDESIGN:Hospital-basedSETTING:PatientsrecruitedQiluHospitalShandongUniversityPARTICIPANTS:258cases282healthyMETHODS:Multiplicativeassessedcross-productlogisticregressioneffect50µg/Lkg/mpresencecalculationrelativeexcessattributableproportionsynergyRESULTS:ORsferritin-BMIproductmultiplicativemodels943904984951059alsoevidence314026506107017241194053406adjustingpotentialconfoundersestimatesCIsaforementionedthreemeasures311191039774285CONCLUSIONS:ChinesepopulationinvestigationsbigsamplesizenecessaryconfirmingJointeffectsdisease:Nutrition&DieteticsPublicHealth

Similar Articles

Cited By (2)